Erez Daniel, Shefler Coral, Roitman Eytan, Levy Sigal, Dovrish Zamir, Ellis Martin, Twito Orit
Department of Medicine D, Meir Medical Center, Kfar Saba, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medicine A, Meir Medical Center, Kfar Saba, Israel.
Endocr Pract. 2022 Feb;28(2):129-134. doi: 10.1016/j.eprac.2021.10.005. Epub 2021 Nov 3.
Anemia is a known complication of diabetes mellitus (DM); however, its prevalence and prognostic relevance in patients with DM and pre-DM with normal kidney function have not been well defined. This study assessed the prevalence of anemia in patients with DM and pre-DM and evaluated its association with clinical outcomes during a 4-year follow-up period.
This retrospective analysis included patients with DM and pre-DM referred to the Meir Medical Center Endocrine Institute in 2015. Patients with an estimated glomerular filtration rate (eGFR) of <60 mL/min or any other recognized cause of anemia were excluded. The risk of developing microvascular or macrovascular complications or of death during the 4-year follow-up period was determined.
A total of 622 patients (408 with DM and 214 with pre-DM) were included. The mean age of the patients was 64 ± 10.6 years, and 70% were women. The baseline hemoglobin A1C level was 7.1% ± 1.7% (54 mmol/mol), and the eGFR was 86.1 ± 15.3 mL/min. At the time of inclusion, 77 patients (19%) with DM and 23 (11%) with pre-DM had anemia (hemoglobin level 11.9 ± 0.8 and 11.8 ± 0.8 g/dL, respectively), compared with normal hemoglobin levels of 13.8 ± 0.9 and 13.7± 0.9 g/dL, respectively, in the others. A multivariable analysis demonstrated an inverse correlation between baseline hemoglobin (as a continuous variable) and mortality (P = .035), microvascular complications (P = .003), and eGFR decline (P < .001) but not between baseline hemoglobin and macrovascular complications (P = .567).
This study found a significant prevalence of anemia unrelated to renal failure, both in patients with DM and pre-DM. Anemia in these patients is associated with the development of microvascular complications, eGFR decline, and mortality. These results underscore the need for intensive lifestyle and pharmacologic interventions in these patients.
贫血是糖尿病(DM)的一种已知并发症;然而,其在肾功能正常的糖尿病患者和糖尿病前期患者中的患病率及预后相关性尚未明确界定。本研究评估了糖尿病患者和糖尿病前期患者贫血的患病率,并在4年随访期内评估了其与临床结局的关联。
这项回顾性分析纳入了2015年转诊至梅尔医学中心内分泌研究所的糖尿病患者和糖尿病前期患者。排除估计肾小球滤过率(eGFR)<60 mL/分钟或任何其他已知贫血病因的患者。确定4年随访期内发生微血管或大血管并发症或死亡的风险。
共纳入622例患者(408例糖尿病患者和214例糖尿病前期患者)。患者的平均年龄为64±10.6岁,70%为女性。基线糖化血红蛋白A1C水平为7.1%±1.7%(54 mmol/mol),eGFR为86.1±15.3 mL/分钟。纳入时,408例糖尿病患者中有77例(19%)、214例糖尿病前期患者中有23例(11%)患有贫血(血红蛋白水平分别为11.9±0.8和11.8±0.8 g/dL),其余患者的正常血红蛋白水平分别为13.8±0.9和13.7±0.9 g/dL。多变量分析显示,基线血红蛋白(作为连续变量)与死亡率(P = 0.035)、微血管并发症(P = 0.003)和eGFR下降(P < 0.001)呈负相关,但与基线血红蛋白和大血管并发症之间无相关性(P = 0.567)。
本研究发现,在糖尿病患者和糖尿病前期患者中,与肾衰竭无关的贫血患病率很高。这些患者的贫血与微血管并发症的发生、eGFR下降和死亡率相关。这些结果强调了对这些患者进行强化生活方式和药物干预的必要性。